Post-Covid-19 War Era, Updates Medicare and Medicaid Difference Between Young Versus Old

Short Communication

Post-Covid-19 War Era, Updates Medicare and Medicaid Difference Between Young Versus Old

Bahram Alamdary Badlou ^*

BBAdvies and Research, Research and Development Dept. Zeist, The Netherlands.

*Corresponding Author: Bahram Alamdary Badlou, BBAdvies and Research, Research and Development Dept. Zeist, The Netherlands.

Citation: Badlou BA. (2026). POSTCOVID-19 WAR Era, Updates Medicare and Medicaid Difference Between Young Versus Old, International Journal of Biomedical and Clinical Research, BioRes Scientia Publishers. 6(2):1-3. DOI: 10.59657/2997-6103.brs.26.115

Copyright: © 2026 Bahram Alamdary Badlou, this is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Received: December 29, 2025 | Accepted: January 14, 2026 | Published: January 22, 2026

Abstract

Keywords: human; vivo; POSTCOVID-19; prognostics; diagnostics, medicare; medicaid

The recent rise in aging‑related diseases, combined with COVID-19-associated infections and pro‑inflammatory clinical manifestations in long-COVID patients, has contributed to delays and biases in carrying out appropriate Pro-Diagnostics and related Medicare and Medicaid (PDM&M) actions. According to various published WHO reports, an estimated 400 to 600 million people worldwide may be experiencing long-COVID or post-COVID-19 clinical symptoms (December 2025).

In this POSTCOVID-19 WAR periods, differences between old-fashioned and modern medical responses have caused more than 65 million people (about twice the population of California) to 650 million worldwide, are suffering from long covid clinical indications, which the underlying mechanisms still have not been elucidated completely [1-17]. What could be done to restore public trusts over Medical Scientists now (November 2025)? Different updated and (not retracted yet) publications in the last 4-5 years indicate that there are significant differences between young versus old subjects who are suffering from the same diseases. Moreover, there are significant differences between men and women affected by the same symptoms and pathologic processes. Besides, certain infections which are not detectable by modern prognostic/ diagnostics tools either AI-dependent or independent, still their mechanisms of action are not completely elucidated yet. Moreover, overall updates and upgrades are needed to protect different patients against unpredictable disease progression, radically. On the other hand, reconsideration of old -fashioned guidelines, and SOPs, either depending on certain model systems, and/or approved pre-covid mechanisms, is a prerequisite condition to transform novel approaches and build public trust, however. Infectious agents and novel superbugs are playing pivotal role between different angles of the death triangle, which could play an essential role as a lifesaving novel idea, as predicted [3]. Different fact-based data processed and presented by respectful organizations worldwide indicate that excessive increased morbidity and mortality rates are indisputable facts, in this postcovid-19 period. The sincere questions remain Why? When? How does such acceleration of disease progression take place? What is known? And what is unknown yet that could be elucidated, eventually [1-3].

To highlight the complex interplay between aging-related diseases, management of new long COVID clinical indications, more than 200 different rare symptoms reported oddly. And the strain on Medicare and Medicaid systems, a breakdown of what’s happening now to follow up rapid mutations is required/ demanded by different chronic patients. Besides, what could be done to address these challenges in Medicare and Medicaid is a perquisite condition, before any expensive approach(s) could be implemented, in this POST COVID-19 period [1,2,5].

The Current Landscape is divided into different novel categories, i.e. 1. Long COVID prevalence aspects: Among Medicare beneficiaries, nearly 140,000 for instance in Nederland but more than 65 million in US, were diagnosed with long COVID clinical indications, lasting over a year, based on recent data from 3.6 million patients. This is just a fraction of the estimated +-650 million globally affected. 2. Aging population vulnerability increased however, and (non-COVID) erosion-related distressed aspects i.e. older adults are more susceptible to long COVID due to pre-existing conditions and immune system decline, which complicates diagnosis and treatment. 3. Medicare/Medicaid strain: in post pandemic-era, Medicaid continuous offering (un) uniform coverage has led to mass disenrollments, increasing the risk of uninsured status and disrupting care continuity [4].

significant failure to work with old fashion SOPs’ gaps resulted in legacy system, and profoundly outdated protocols in healthcare that are not working appropriately. Furthermore, administrations are struggling to adapt to the evolving needs of different post-COVID care demands between different genders, ages, and ethnicities, (un)intentionally.

What could be done hypothetically? There are potentially different possibilities, like 1. Try to Modernize Healthcare SOPs, 2. Try to Integrate AI-driven diagnostics and remote monitoring for long COVID symptoms. 3. Update clinical guidelines to reflect long COVID’s multi-systemic nature, especially in geriatric care. 4. Try to expand Coverage and Access i.e. Reinstate or redesign Medicaid continuous coverage policies to prevent gaps in care.; Increase funding for long COVID clinics and rehabilitation programs under Medicare. 5. Try to Enhance fact-based field’ data and Surveillance i.e. try to use Medicare and Medicaid claims data to track long COVID trends and identify high-risk populations [1-3]. Encourage cross-agency collaboration to unify data standards and improve response times. 6. Promote Preventive Measures i.e., Boost vaccination campaigns, especially among older adults >50 y, as more doses are linked to lower long COVID risks. Educate providers and patients on early symptom recognition and management. in The Journal of Gerontology analyses Medicare data from 3,588,671 Medicare beneficiaries diagnosed as having COVID-19 from October 2021 to March 2023 and finds that 3.9% of beneficiaries-or about 140,000 people-were diagnosed with long COVID after experiencing symptoms for at least 1 year [1]. 7. Support Research and Innovation i.e. support and Fund different studies on aging-related inflammation and its role in long COVID. Develop personalized treatment pathways using genomics and precision medicine.

Platelets functions in between are remaining unknown questions, in this post Covid -19 war period (2025). Recently, different study groups reported that platelets-microbial interactions remain unknown [4-7]. It is noteworthy that in different nucleated cells, necroptosis and pyroptosis lead to the release of danger-associated molecular and cellular patterns i.e. calprotectin [8] and not yet elucidated molecular changes. On the other hand, another relevant factor is human blood Platelets from patients infected with COVID-19, who have been shown to passively release certain (unknown yet) amino acids and reported proteins between donors [8], indicating a significant difference between COVID-19 infected and not infected donors. Previous studies indicated that amino acids release and some proteins are involved in excessive release of inflammatory cytokines and disease-progression severity, eventually [8-12] Simultaneously increased platelet levels may contribute to amplified pathologic changes between endothelial cells, and induce unknown internal Patho-physiologies, however [13]. MI and other thrombotic complications [13-15] in plasma of the subjects infected with COVID-19 also have been shown that some plasma protein contains that could functionally increase pathogenic processes associated with severity levels, which were assessed to be an independent predictor of worse clinical outcome, between contracted patients [16]. If samples would be available a genomic and proteomics analysis might help to assess certain COVID-19 variants can lead to direct release platelet 's proteins and glycoproteins [17] rather than by old fashioned triple A's platelet activation, as reported previously [8-16].

Taken together, many clinical symptoms and their pathophysiologies remained unknown and still not elucidated completely. In this post COVID-19 period, for example platelets-microorganisms' interactions remained unknown, whether they are age-dependent or not? Whether they are involved in severity of cancerogenic processes or not? Many research groups with or without nanotechnologies tools described based on their data reported that their results could not show direct correlation with certain mutants, which profoundly indicate that the most of them had no clue over exact mechanism of COVID-19 mutants and superbugs mechanism of action that were synthetically created from simple corona viruses, pre-pandemic periods. The most essential aspect is previously introduced by my novel invented model system before the COVID-19 pandemic attacks, since 2018 that might interaction of microorganisms and cancerogenic processes accelerate mortality and morbidity rates, however. Reconsideration of bidirectional interactions’ angle between Hematologic specially PLTs-- microorganisms (either viral or bacterial) is recommended and need more in detail investigation (December 2025).

Conflict of Interest

The author declares no conflict of interest of any kind.

References

Stephanie Soucheray, (2025). Long-COVID diagnoses fairly common in Medicare claims, News Brief.
Publisher | Google Scholor
Abul, Y., Harris, D. A., Chachlani, P., Hayes, K. N., Zullo, A. R., et al. (2025). Incidence of Long COVID diagnoses in 3.6 million US Medicare beneficiaries with COVID-19. The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 80(7):glaf108.
Publisher | Google Scholor
Badlou, B. A. (2024). POSTCOVID-19 WAR Era, Abnormally Some Patients being Affected by Exceptional Disease Progression, and Accelerated Excessive Mortality Rate. Archives of Pharmacology and Therapeutics, 6(1):24-26.
Publisher | Google Scholor
Kobsar, A., Vaz, D. S., Zeller-Hahn, J., Koessler, A., Weber, K., et al. (2025). TLR2-induced surface mobilization and release of CD14 in human platelets. Scientific Reports, 15(1):35572.
Publisher | Google Scholor
Sciaudone, A., Corkrey, H., Humphries, F., Koupenova, M. (2023). Platelets and SARS-CoV-2 during COVID-19: immunity, thrombosis, and beyond. Circulation Research, 132(10):1272-1289.
Publisher | Google Scholor
Koupenova, M., Corkrey, H. A., Vitseva, O., Tanriverdi, K., Somasundaran, M., et al. (2021). SARS-CoV-2 initiates programmed cell death in platelets. Circulation Research, 129(6):631-646.
Publisher | Google Scholor
Junqueira, C., Crespo, Â., Ranjbar, S., De Lacerda, L. B., Lewandrowski, M., et al. (2022). FcγR-mediated SARS-CoV-2 infection of monocytes activates inflammation. Nature, 606(7914):576-584.
Publisher | Google Scholor
Kolb, J. P., Oguin, T. H., Oberst, A., Martinez, J. (2017). Programmed cell death and inflammation: winter is coming. Trends in Immunology, 38(10):705-718.
Publisher | Google Scholor
Xia, C., Braunstein, Z., Toomey, A. C., Zhong, J., Rao, X. (2018). S100 proteins as an important regulator of macrophage inflammation. Frontiers in Immunology, 8:1908.
Publisher | Google Scholor
Su, M., Chen, C., Li, S., Li, M., Zeng, Z., et al. (2022). Gasdermin D-dependent platelet pyroptosis exacerbates NET formation and inflammation in severe sepsis. Nature Cardiovascular Research, 1(8):732-747.
Publisher | Google Scholor
Colicchia, M., Schrottmaier, W. C., Perrella, G., Reyat, J. S., Begum, J., et al. (2022). S100A8/A9 drives the formation of procoagulant platelets through GPIbα. Blood, The Journal of the American Society of Hematology, 140(24):2626-2643.
Publisher | Google Scholor
Mahler, M., Meroni, P. L., Infantino, M., Buhler, K. A., Fritzler, M. J. (2021). Circulating calprotectin as a biomarker of COVID-19 severity. Expert Review of Clinical Immunology, 17(5):431-443.
Publisher | Google Scholor
Barrett, T. J., Cornwell, M., Myndzar, K., Rolling, C. C., Xia, Y., et al. (2021). Platelets amplify endotheliopathy in COVID-19. Science Advances, 7(37):eabh2434.
Publisher | Google Scholor
Lood, C., Tydén, H., Gullstrand, B., Jönsen, A., Källberg, E., et al. (2016). Platelet-derived S100A8/A9 and cardiovascular disease in systemic lupus erythematosus. Arthritis & Rheumatology, 68(8):1970-1980.
Publisher | Google Scholor
Wang, Y., Fang, C., Gao, H., Bilodeau, M. L., Zhang, Z., et al. (2014). Platelet-derived S100 family member myeloid-related protein-14 regulates thrombosis. The Journal of Clinical Investigation, 124(5):2160-2171.
Publisher | Google Scholor
Clancy, L., Beaulieu, L. M., Tanriverdi, K., Freedman, J. E. (2017). The role of RNA uptake in platelet heterogeneity. Thrombosis and Haemostasis, 117(05):948-961.
Publisher | Google Scholor
Koupenova, M., Corkrey, H. A., Vitseva, O., Tanriverdi, K., Somasundaran, M., et al. (2021). SARS-CoV-2 initiates programmed cell death in platelets. Circulation Research, 129(6):631-646.
Publisher | Google Scholor

Delia Teresa Sponza

"Journal of BioMed Research and Reports has created a diverse portfolio in peer review process and provides a wide range scientific and medical novel papers to the scientists. This journal publishes high-quality, peer-reviewed content across all levels of professional development and corporate research and development."

Fatema Tashrifwala

I would like to thank the editorial team for their timely responses and consideration in the publication of my paper. They have been very helpful and accommodating, Lastly, being an open access journal, the published work is freely available and accessible to readers at no cost to them. I would encourage other authors to publish their research in BioRes Scientia. I am happy to be a part of BioRes Scientia Publishers.

Dr Nikhil Vitthal Dayama

I would like to thank the editorial team for their timely and prompt responses and consideration in the publication of my case report. Being an open access journal, it will be great help for the readers to learn the new things without any cost. I would encourage the authors to publish their research in BioRes Scientia and I am happy to be part of this journal.

Boubacar Ahy Diatta

I warmly thank the editorial team for the excellent work they do for continuing medical education in Dermatology. I was able to discover with joy their professionalist, their support and above all appreciate their social generosity on the access to the magazines which is free. This allows an update of scientific knowledge to the entire scientific community. I gladly recommend authors for publication in this journal.

Professor Rajko Igic

The editor of JBRR helped me during the whole process, mainly to eliminate some typographical and other errors. It hastened this publication to be published quickly. Although it is a short text, I believe that the content is important for all medical and other scientific disciplines because eventual addition of the iC citations to citation of the paper would lead to proper assessment of the author's contribution.

Dr Tewodros kassahun Tarekegn

I am thrilled to have had the opportunity to publish my research article in this prestigious journal. The entire process of peer review and publication support provided by the editorial office was exceptional, and it fortified my belief in the quality of my research study. The rigorous peer review process ensured that only the highest quality research was published, and the feedback from the reviewers was extremely helpful. I appreciate the journal's commitment to open access publication, enabling my research to reach a wider audience. The easy-to-use online platform streamlined the submission, peer review, and publication process, and I would confidently recommend this journal to any author looking for efficient, rigorous, and high-quality peer-reviewed publication.

Francis Okello Ooko

I was impressed by your author-centred approach whereby you maintained constant and timely communication with us from the time we submitted the manuscript to acceptance, each time providing critical suggestions to improve the manuscript. In addition, we are encouraged by the thoroughness of your editorial team in checking the originality and overall, quality of the work. Which I believe is very encouraging to other researchers and authors who wish to publish their work in your journals. The published work and the information imparted is freely available and accessible to a wide spectrum of readers at no cost to them. I would encourage other authors to publish their research in BioRes Scientia. I am happy to be a part of BioRes Scientia Publishers.

Dr Nidhi Sapolia

I would like to thank the editorial team of their timely response and guidance in the publication of my case report. They have been extremely helpful at all stages. Being an open access journal, it is of great help for the readers to learn new experiences in different fields, I would highly recommend this journal to authors for high quality peer-reviewed publications.

Dwight L Mckee MD CNS ABIHM

I am very impressed by the high quality of the papers published by the International Journal of Clinical and Molecular Oncology. The editors of this journal are a pleasure to work with, as they are highly responsive even to numerous last minute changes in the manuscript that I recently published with them, and the changes are made on-line the same day they are received. I highly recommend this journal to anyone working in the oncology field, and also value it as a source of cutting edge information in the field.

Kyaw Swar Thet

I would like to thank the editorial team for the opportunity to publish our case report in this prestigious journal. I am very impressed by their timely and efficient handling of the submission, peer review, and publication processes. As residents of a developing, low-income country, we greatly appreciate the discount on submission charges. I hope that as an open access journal, it will facilitate easy access for readers to update their scientific knowledge. I highly recommend this journal for high-quality, peer-reviewed publications. I express my sincere gratitude to the editorial team for their excellent work.

Michel Farah

I would like to thank the editorial team for their quick response and support. The publication support and editorial office were excellent and very helpful. I am happy to have my research article published in this prestigious journal. Our previous case report published in this journal was very successful and viewed by many physicians worldwide.

Kristina Dimitrijevic

I am very positively surprised by thе International Journal of Biomedical and Clinical Research, as well as by the review process itself, which is carried out in a high-quality, timely and professional manner. I am glad that my articles are part of this journal.

Hamid Kasim

I had the pleasure of working with your esteemed journal. I testify that the peer review process was effective and quick, the support from the editorial office is very professional, respectful and friendly and the quality of the review is objective and accurate. I am grateful for the opportunity to work with International Journal of Biomedical & Clinical Research and looking forward for more future cooperation.

Ochala Ejura J

The interaction with the Journal of Women Health Care and Gynaecology has been seamless. I wish to express my profound appreciation to your expert editorial team for the timely response and support. The feedbacks from the peer review process was of great help. Thank you for the discount and opportunity to publish in your reputable journal. I believe that being an Open access journal, it will enable readers easy access to to update their knowledge. I would recommend BioRes Scientia publishers and look forward to more collaborations.

Fernando M Clara

I would like to thank the Journal of Clinical Cardiology and Cardiology Research for the opportunity to publish our work. We greatly appreciate the professionalism demonstrated throughout the editorial process. The rapid peer review, along with the high-quality graphic design, streamlined the process and significantly improved the final presentation of our manuscript. The Journal’s support for scientific dissemination is a meaningful incentive for ongoing research. We commend your editorial efforts and extend our best wishes for the Journal's continued success.

Dr Stylianos Sergios Chatziioannou

Journal of BioMed Research and Reports process was constructive and timely, ensuring that the scientific rigor of the manuscript was upheld. Communication with the editorial office was smooth and supportive throughout, making the overall publication experience very positive. I appreciate the efforts of the editorial team in maintaining high-quality standards, and I am confident that the journal will continue to grow in impact and recognition.

Dr C Zeroual

I am pleased to have worked with the Journal of Brain Research and Neurology. The editorial team was responsive and supportive throughout the process, and the peer review was handled efficiently. I appreciate the opportunity to contribute to this journal and look forward to future collaborations

Mohammadreza Kashefi Baher

I am pleased to have published my research in Dentistry and Oral Health Care. The peer review process was efficient and respectful, and I appreciated the timely communication and support from the editorial team. The journal maintains a professional standard and provides an accessible platform for sharing scientific work. I am grateful for the opportunity and look forward to contributing again in the future.

Cidalia De Fatima Cabral De Frias

I would like to thank the editorial team of International Journal of Biomedical and Clinical Research for their prompt and timely responses during the review process of my article. I had the opportunity to share with the academic community my understanding of the process of caring for a person at the end of life. I recommend the publication of research in the area of palliative care in this prestigious journal.

Roxana Maria Hoza

The peer review process at Hematology Research and Blood Disorders is fair and constructive. The editorial office provides excellent support and timely communication. The journal maintains high quality and is a trusted platform for hematology research.

Dr Hamid Kasim

I was very pleased to collaborate with your esteemed Journal of BioMed Research and Reports, and I also thank the editorial board and the reviewers who enriched my article with their very helpful comments, resulting in a beautiful and elegant presentation. I hope our collaboration will continue in the future, With my respect and best wishes for your continued success.